ScripPublic biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo
ScripNektar Therapeutics is making Phase III preparations for rezpegaldesleukin, also known as rezpeg, after the potential pipeline-in-a-product hit its main goal in a mid-stage trial for patients with ato
ScripIt looks as though nothing will come of the takeover talks PureTech Health has held with Nordic Capital Epsilon but there is a compelling argument for taking its ‘hub-and-spoke’ business private in th
ScripWho: Grünenthal/Valinor Pharma What: Grünenthal is buying privately held US biotech Valinor on the strength of its lone commercial product, Movantik. Why: Grünenthal is acquiring Valinor to gain